These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

664 related articles for article (PubMed ID: 30357541)

  • 1. Current Clinical Trials in Non-muscle Invasive Bladder Cancer.
    Nykopp TK; Batista da Costa J; Mannas M; Black PC
    Curr Urol Rep; 2018 Oct; 19(12):101. PubMed ID: 30357541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
    Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder Cancer.
    Roumiguié M; Kamat AM; Bivalacqua TJ; Lerner SP; Kassouf W; Böhle A; Brausi M; Buckley R; Persad R; Colombel M; Lamm D; Palou-Redorta J; Soloway M; Brothers K; Steinberg G; Lotan Y; Sylvester R; Alfred Witjes J; Black PC
    Eur Urol; 2022 Jul; 82(1):34-46. PubMed ID: 34955291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapies in non-muscle invasive bladder cancer: immunotherapies and NMIBC].
    Loriot Y; Rouprêt M
    Bull Cancer; 2020 Jun; 107(5S):S49-S55. PubMed ID: 32620207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
    Kim HS; Seo HK
    Investig Clin Urol; 2021 Jul; 62(4):361-377. PubMed ID: 34085791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of high-risk non-muscle invasive bladder cancer.
    Brausi M; Olaru V
    Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC.
    Wright KM
    Oncology (Williston Park); 2020 Feb; 34(2):44. PubMed ID: 32645193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatment landscape of non-muscle invasive bladder cancer.
    Valenza C; Antonarelli G; Giugliano F; Aurilio G; Verri E; Briganti A; Curigliano G; Necchi A
    Expert Opin Biol Ther; 2022 Jun; 22(6):717-734. PubMed ID: 35634893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of treatment of high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) patients among Arab urologists.
    Moussa M; Abou Chakra M; Shore ND; Papatsoris A; Farahat Y; O'Donnell MA
    Arch Ital Urol Androl; 2024 Mar; 96(1):12244. PubMed ID: 38502039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to enhance the efficacy of intravescical therapy for non-muscle invasive bladder cancer.
    Smaldone MC; Gayed BA; Tomaszewski JJ; Gingrich JR
    Minerva Urol Nefrol; 2009 Jun; 61(2):71-89. PubMed ID: 19451890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
    Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
    Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nadofaragene Firadenovec: First Approval.
    Lee A
    Drugs; 2023 Mar; 83(4):353-357. PubMed ID: 36856952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.
    Balar AV; Kamat AM; Kulkarni GS; Uchio EM; Boormans JL; Roumiguié M; Krieger LEM; Singer EA; Bajorin DF; Grivas P; Seo HK; Nishiyama H; Konety BR; Li H; Nam K; Kapadia E; Frenkl T; de Wit R
    Lancet Oncol; 2021 Jul; 22(7):919-930. PubMed ID: 34051177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel intravesical therapies for non-muscle-invasive bladder cancer refractory to BCG.
    Barlow LJ; Seager CM; Benson MC; McKiernan JM
    Urol Oncol; 2010; 28(1):108-11. PubMed ID: 20123359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage.
    Balasubramanian A; Gunjur A; Weickhardt A; Papa N; Bolton D; Lawrentschuk N; Perera M
    World J Urol; 2022 May; 40(5):1111-1124. PubMed ID: 35083522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Adjuvant instillation therapy for non-muscle invasive bladder cancer - beyond BCG and mitomycin C].
    Gakis G
    Aktuelle Urol; 2022 Apr; 53(2):148-152. PubMed ID: 35172349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
    Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
    Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
    Mitra AP; Narayan VM; Mokkapati S; Miest T; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown GA; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Philipson R; Ylä-Herttuala S; Sawutz D; Parker NR; McConkey DJ; Dinney CPN
    Eur Urol; 2022 Mar; 81(3):223-228. PubMed ID: 34933753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.